Equities

Fibrobiologics Inc

Fibrobiologics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.24
  • Today's Change-0.14 / -5.88%
  • Shares traded1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 20 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

FibroBiologics Inc is a United States-based company. The Company operates as a biopharmaceutical company. It is focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. It also develops biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal.

  • Revenue in USD (TTM)0.00
  • Net income in USD-17.78m
  • Incorporated2021
  • Employees10.00
  • Location
    Fibrobiologics Inc455 E. Medical Center Blvd, Suite 300HOUSTON 77598United StatesUSA
  • Phone+1 (281) 671-5150
  • Fax+1 (302) 655-5049
  • Websitehttps://fibrobiologics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Regencell Bioscience Holdings Ltd0.00-4.30m74.17m12.00--9.02-----0.3306-0.33060.000.63160.00----0.00-41.44-56.31-42.99-77.51------------0.00------26.73------
PDS Biotechnology Corp0.00-40.56m74.56m25.00--3.39-----1.17-1.170.000.59750.00----0.00-73.98-51.63-98.74-59.00-----------19.130.5286-------5.11------
VolitionRX Ltd1.29m-29.87m74.60m110.00------58.02-0.3623-0.36230.0155-0.23280.0837--7.4111,689.36-196.61-111.92---196.20-----2,348.71-10,793.31---104.15----153.04---16.68--29.13--
Armata Pharmaceuticals Inc5.47m-41.36m75.62m66.00------13.83-1.24-1.240.1312-1.410.0518--1.0282,833.34-39.21-59.78-116.66-72.70-----756.59-1,113.72----1.90---17.77---87.03--184.10--
Aerovate Therapeutics Inc0.00-84.61m76.79m51.00--0.954-----2.99-2.990.002.790.00----0.00-72.99---81.83--------------0.00-------46.61------
ESSA Pharma Inc0.00-27.67m76.79m50.00--0.5957-----0.6257-0.62570.002.900.00----0.00-19.33-23.01-19.81-23.67------------0.00------24.27------
Fibrobiologics Inc0.00-17.78m77.64m10.00--27.76-----0.8864-0.88640.000.08070.00----0.00-149.60---225.38--------------0.0403-------272.15------
Chimerix Inc159.00k-83.59m79.14m72.00--0.5829--497.76-0.9351-0.93510.00181.510.0008--1.922,208.33-43.54-30.45-48.29-34.092.52---52,574.84-442.93----0.00---99.04-46.24-147.68---13.24--
CervoMed Inc10.07m-11.95m79.57m8.00--1.74--7.90-1.60-1.601.355.530.3305----1,258,319.00-39.22-53.67-43.28-58.89-----118.68-949.54----0.00------86.07------
Quince Therapeutics Inc0.00-53.26m79.63m32.00--1.77-----1.25-1.250.001.040.00----0.00-50.27-42.72-52.16-46.06------------0.249------39.25---5.47--
Clearside Biomedical Inc7.70m-31.88m79.64m30.00------10.34-0.4503-0.45030.1094-0.46540.2423--9.23256,766.70-100.27-63.57-122.24-81.7797.01---413.83-231.80--------519.89207.341.40--82.41--
Adicet Bio Inc0.00-117.88m79.69m143.00--0.3767-----1.70-1.700.002.570.00----0.00-49.20-37.03-53.58-40.28-------748.46----0.00---100.00---104.41--65.27--
Sellas Life Sciences Group Inc0.00-32.28m79.77m16.00--5.02-----0.7113-0.71130.000.24680.00----0.00-186.64-111.48-527.32-184.29-------1,289.42----0.00---100.00--9.59------
Renovaro Inc0.00-115.69m79.96m25.00--0.8096-----0.9343-0.93430.000.62230.00----0.00-128.97-39.86-158.19-42.11-----------9.650.0259-------103.23---37.12--
MDxHealth SA80.74m-40.80m80.19m300.00------0.9931-1.54-1.543.06-0.32290.59069.397.49269,136.70-29.85-51.62-43.63-64.7262.6450.88-50.54-117.640.8252-1.741.18--89.4319.842.14--30.13--
Data as of Nov 20 2024. Currency figures normalised to Fibrobiologics Inc's reporting currency: US Dollar USD

Institutional shareholders

12.26%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20241.63m4.63%
The Vanguard Group, Inc.as of 30 Sep 2024715.96k2.04%
Geode Capital Management LLCas of 30 Sep 2024599.76k1.71%
SSgA Funds Management, Inc.as of 30 Sep 2024475.84k1.35%
Cascade Financial Partners LLCas of 30 Sep 2024302.60k0.86%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024210.47k0.60%
Optive Advisory Services LLCas of 30 Sep 2024110.10k0.31%
Requisite Capital Management LLCas of 30 Sep 2024109.71k0.31%
American Institute for Advanced Investment Management LLPas of 30 Sep 202488.21k0.25%
Morgan Stanley & Co. LLCas of 30 Sep 202470.12k0.20%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.